Cardinal Health, Inc.'s Stock Analysis

Cardinal Health Raises $1 Billion Through Public Notes Offering

Cardinal Health, Inc. completed a public offering totaling $1 billion, comprising $600 million in 4.500% Notes due 2030 and $400 million in 5.150% Notes due 2035. The proceeds from this offering will primarily be used to fund the acquisition of Solaris Health, as well as cover associated fees and expenses. Until the proceeds are allocated for the acquisition, the company may use them for general corporate purposes.

The Notes are subject to a special mandatory redemption if the acquisition is not completed by August 12, 2026, or if the company decides not to pursue the acquisition. In such cases, the Notes will be redeemed at 101% of their principal amount, plus any accrued interest. The offering was conducted under an effective registration statement previously filed with the SEC, and the legal opinions regarding the issuance of the Notes were provided by the company’s counsel.

Aug 27, 2025 17:02:44

Cardinal Health Issues $1 Billion in New Notes Offering

Cardinal Health, Inc. has entered into an underwriting agreement to sell $600 million of 4.500% Notes due 2030 and $400 million of 5.150% Notes due 2035. This offering is conducted under the company's effective registration statement filed with the Securities and Exchange Commission.

The underwriting agreement involves Goldman Sachs & Co. LLC, BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives of the underwriters. A complete copy of the Underwriting Agreement is available as an exhibit in the current report.

Aug 14, 2025 17:06:21

Cardinal Health Announces Fiscal 2025 Results and Acquisition Plans

Cardinal Health reported fourth quarter fiscal year 2025 revenues of $60.2 billion, which remained relatively flat compared to the same quarter in fiscal year 2024. Excluding the impact of a previously communicated customer contract expiration, revenue increased by 21%. The company reported GAAP operating earnings of $428 million, with a GAAP diluted earnings per share (EPS) of $1.00. Non-GAAP operating earnings rose 19% to $719 million, and non-GAAP diluted EPS increased 13% to $2.08. For the entire fiscal year 2025, revenues totaled $222.6 billion, marking a 2% decrease from the previous year, but an 18% increase when excluding the contract expiration effect.

Additionally, Cardinal Health announced the acquisition of Solaris Health, a leading urology management services organization, as part of its growth strategy. The company raised its non-GAAP EPS guidance for fiscal year 2026 to a range of $9.30 to $9.50, reflecting anticipated growth driven by contributions from its Pharmaceutical and Specialty Solutions segment. Cardinal Health's fiscal year 2025 adjusted free cash flow was reported at $2.5 billion, indicating strong cash generation capabilities.

Aug 12, 2025 06:59:12

Cardinal Health Raises EPS Guidance and Long-Term Growth Targets

Cardinal Health has updated its fiscal year 2025 guidance, raising the non-GAAP diluted EPS to a range of $8.15 to $8.20, reflecting a 9% growth at the midpoint. The company also provided preliminary guidance for fiscal year 2026, estimating non-GAAP diluted EPS between $9.10 and $9.30, which indicates a growth of 13% at the midpoint. Additionally, Cardinal Health has raised its long-term targets for profit growth in its Pharmaceutical and Specialty Solutions segment to 5% to 7% and for Other profit to approximately 10% normalized growth.

The company expects to generate at least $10 billion in total adjusted free cash flow over the next three years and has increased its baseline share repurchase plans to at least $750 million per year. Cardinal Health continues to focus on strategic priorities, including investments in its Pharmaceutical Distribution and Specialty Solutions, and plans to invest at least $600 million annually in capital expenditures to support organic growth across its businesses.

Jun 12, 2025 06:47:01

Cardinal Health Reports Flat Revenue, Raises EPS Guidance for 2025

Cardinal Health announced its third quarter fiscal year 2025 results, reporting revenue of $54.9 billion, which remained flat compared to the same quarter in the previous year. Excluding the impact of a customer contract expiration, revenue increased by 19%. The company's GAAP operating earnings reached $730 million, and GAAP diluted earnings per share (EPS) were $2.10. Non-GAAP operating earnings increased by 21% to $807 million, with non-GAAP diluted EPS rising by 13% to $2.35, reflecting segment profit growth across all operating segments.

The company has raised and narrowed its fiscal year 2025 non-GAAP EPS guidance to a range of $8.05 to $8.15, up from the previous range of $7.85 to $8.00. This updated guidance includes an increased outlook for segment profit growth in both the Pharmaceutical and Specialty Solutions and Other segments. Additionally, Cardinal Health completed a $375 million accelerated share repurchase program and announced its expansion into the urology specialty therapeutic area through GI Alliance. The company remains focused on operational execution and value creation.

May 01, 2025 06:49:54

Cardinal Health Appoints Two New Directors to Board

Cardinal Health has elected Robert Musslewhite and Sudhakar Ramakrishna as independent directors, effective March 7, 2025. Musslewhite brings over 20 years of leadership experience in healthcare analytics and technology, having served as CEO for two publicly traded companies. He will be part of the Audit and Human Resources and Compensation Committees. Ramakrishna, with extensive experience in technology leadership, will serve on the Audit and Risk Oversight Committees, contributing his expertise in cybersecurity and crisis management to the board.

The appointments were welcomed by Cardinal Health's Chairman Gregory Kenny and CEO Jason Hollar, who emphasized the value of their backgrounds in technology and business strategy. Both directors have held significant positions in various companies, which aligns with Cardinal Health's focus on navigating complex business environments. Their addition to the board is seen as a move to enhance the company's capabilities in technology-oriented healthcare solutions.

Mar 10, 2025 06:53:45

Cardinal Health Reports $55.3 Billion Revenue with EPS Growth

Cardinal Health's second quarter fiscal year 2025 results show a revenue decrease of 4% to $55.3 billion, although revenue increased by 16% when excluding the impact of a major customer contract expiration. The company's GAAP operating earnings rose 9% to $549 million, with a GAAP diluted EPS of $1.65. Non-GAAP operating earnings also increased by 9% to $635 million, primarily due to growth in the Pharmaceutical and Specialty Solutions segment. The company announced the raising of its fiscal year 2025 non-GAAP EPS guidance to a range of $7.85 to $8.00, reflecting a positive outlook following recent acquisitions.

On the downside, the overall revenue decline was attributed to the expiration of a large customer contract, which significantly impacted the Pharmaceutical and Specialty Solutions segment, causing a 4% revenue drop to $50.8 billion. Additionally, while the Global Medical Products and Distribution segment saw a slight revenue increase of 1%, it was largely offset by a write-off of uncollectible receivables in the WaveMark business. The company also reported increased interest and other expenses due to new debt financing, which could affect future profitability.

Jan 30, 2025 06:51:39

Company Report Filed Under Securities Exchange Act of 1934

The company has submitted a report in compliance with the Securities Exchange Act of 1934, ensuring transparency and adherence to regulatory requirements. This action reflects the company's commitment to maintaining proper governance and reporting standards. However, the press release lacks detailed financial information or specific performance metrics, which may limit stakeholders' ability to assess the company's current financial health and operational status.

Nov 22, 2024 16:46:52

Cardinal Health Acquires GI Alliance and Advanced Diabetes Supply Group

Cardinal Health has announced the acquisition of a majority stake in GI Alliance for approximately $2.8 billion and the Advanced Diabetes Supply Group for about $1.1 billion. These strategic additions are aimed at enhancing Cardinal Health's multi-specialty growth and at-home solutions, respectively. The acquisitions are expected to improve patient care and expand Cardinal Health’s operational capabilities in gastroenterology and diabetes management. The company anticipates these transactions to contribute positively to revenue and earnings within the first year following their completion.

However, the acquisitions involve significant cash expenditures, totaling around $3.9 billion, which may impact Cardinal Health's financial flexibility in the short term. The company plans to finance these transactions through a combination of cash and new debt, raising concerns about its debt levels. Additionally, the successful completion of these acquisitions is contingent upon obtaining regulatory approvals, which introduces uncertainty regarding their finalization and potential benefits.

Nov 12, 2024 06:20:30

Cardinal Health Reports $52.3 Billion Revenue in Q1 FY25

Cardinal Health's first quarter revenue for fiscal year 2025 was $52.3 billion, reflecting a 4% decrease compared to the same period last year. However, excluding the impact of a large customer contract expiration, revenue increased by 15%. The company reported GAAP operating earnings of $568 million and a GAAP diluted earnings per share (EPS) of $1.70. Non-GAAP operating earnings rose by 12% to $625 million, largely driven by growth in the Pharmaceutical and Specialty Solutions segment, which saw segment profit increase by 16% to $530 million despite a 5% drop in revenue due to the contract expiration. Additionally, Cardinal Health raised its non-GAAP EPS guidance for the fiscal year 2025 from $7.55 to $7.70 to a new range of $7.75 to $7.90.

On the downside, the overall revenue decline and the 4% decrease in the Pharmaceutical and Specialty Solutions segment's revenue indicate challenges faced by the company. The Global Medical Products and Distribution segment also experienced a profit drop to $8 million due to higher manufacturing costs, despite a 3% increase in revenue. Cardinal Health's effective tax rate has increased, which, along with rising interest and other expenses, partially offset the benefits from earnings growth. The company's cash and equivalents decreased significantly from $5.1 billion to $2.9 billion, raising concerns about liquidity.

Nov 01, 2024 06:47:40